Sun, Apr 20, 2014, 12:33 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • endoqd endoqd Oct 18, 2004 11:46 AM Flag

    Good DES Manufacturing piece

    MD&DI article summarizes DES manufacturing difficulties. Focuses on BSC recovery and on Cordis problems with Cypher and new products going forward.

    Interesting to note that the coating problems are now leaking out (no pun intended) into general industry press: �Industry observers say that the most significant problem that remains is adequately explaining failures of drug-elution tests, which gauge whether the correct amount of drug has been eluted over a certain period of time.�

    The coating process (particularly methyl methacrylate topcoat) still elude validation efforts. Not a good sign for the commercial viability of Cypher going forward.

    http://www.devicelink.com/mddi/archive/04/10/002.html

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yeah, joker, rad3, and endoqd (to name a few) have a way of shunning anybody who is not pro BSX. Boards are for discussion not cheerleading. Paid pumpers? Probably the same person. Don't dare say anything bad about Taxus! I've been slammed simply because of my name. I post here because nothing ever happens on the SRDX board. The JNJ board sucks and I want to get info on the DES wars.

      "the more time you spend stating your opinion, the less time you have to think about the facts"

      -bs

    • joker:

      <"I can't tell whether you keep purposely missing my point or if you are just being obtuse.">

      I'm not really sure which point you think I have missed, but you certainly seem to object to my trying to make points of my own.

      <"OK, you're right. The time saved is minimal. Feel better?">

      Thank you, but the point I would rather hit home is that jsocolow (who may never post again after his "outing") had something worth contributing.

    • Were you on the debate team in college? lol

      I can't tell whether you keep purposely missing my point or if you are just being obtuse.

      No, I get it, you need to be right.

      OK, you're right. The time saved is minimal. Feel better?

    • joker:

      <"I get that we are stuck with each other....I have to put up with an SRDX long coming to the BSX board to ask a short what he thinks of Taxus.">

      If you will recall, I didn't ask him what he thought of Taxus - I asked him how much time saving there was as a result of better handling. Bias creeps into everything, but less so when recounting a stat than interpreting it.

      I believe him that the time saving is minimal. It doesn't mean stent handling ("deliverability") doesn't influence which stent is used - in fact, without going back to check, I believe he said that all things being equal cardiologists would pick the better handling platform.

      That Taxus handles better than Cypher is a given. That this is a big factor in marketshare is a given.

      But most likely it isn't time savings or primary lesion success that translates better handling into bigger marketshare - it is the more intangible (but none the less important) sense of control, or ease of use, conveyed by the better platform.

    • <"If you are going to suggest people whose opinions don't tow the party line shouldn't contribute here you are asking for a pretty useless exchange of information.">

      My, you do jump to conclusions.

      <"We all have bias. You have some of the most extreme bias on the board.">

      I believe you should have said that I display my bias openly and passionately. I think that is a more honorable behavior than to contain your bias while pretending to be having a dialog.

      You have your style of posting, I have mine.
      I don't expect to be elected prom queen so that frees me to say what I want.

      I don't remember ever telling anyone to go away, shut up, or get lost. I get that we are stuck with each other....I have to put up with an SRDX long coming to the BSX board to ask a short what he thinks of Taxus.

    • joker:

      <"Unlike Foolish, I wouldn't ask a short his opinion, unless I wanted a bash.">

      We all have bias. You have some of the most extreme bias on the board. Are you suggesting we should dismiss anything you say because of it?

      Reread his answer. He has attempted to be balanced despite his personal bias.

      If you are going to suggest people whose opinions don't tow the party line shouldn't contribute here you are asking for a pretty useless exchange of information.

    • annaspop:

      Thanks for all your insights.

    • Hey Doc:

      Are you the Socolow from Illinois and your name is Josh? Nice program Emory but it didn't say you did an Interventional Fellowship so I am not sure what your experience is with delivering stents. Seems you are more into non-invasive. If you were at Emory, what was your opinion of JOhn Douglass and Doug Morris, both men whom I admire and respect?

      R3

      PS...if you are Josh Socolow, you should really change your screenname and go more anonymous. Not good for your practice and reputation to post on these inane MB's...lol

    • jsocolow,
      what is your med background? I was curious as to which hospital you are associated with. For the group at our hospital there is a 50/50 split between Cypher & Taxus, mostly having to do with contracts stipulating use of both. But in terms of deliverability ease the interventional cardiologists here prefer Taxus. I am curious to see the results from the AHA conference...

      HS

    • Dr J posted that he was going short last week.

      Unlike Foolish, I wouldn't ask a short his opinion, unless I wanted a bash.

    • View More Messages
 
BSX
13.65+0.15(+1.11%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.